In response to the rapid spread of the new coronavirus SARS-CoV-2, Bethyl Laboratories has developed ELISA kits for the detection of human IgG and IgM antibodies against the virus in serum or plasma to aid vaccine and other COVID-19 related research.
Using an ELISA to detect SARS-CoV-2 antibodies is typically considered a more efficient choice than a lateral flow immunoassay, which is commonly used for clinical diagnostics due to the speed at which they can be performed. ELISA is also the more sensitive of the two assays.
Together we can accelerate discovery to improve lives.
Quickly detect multiple antigens in a single tissue section to gain clear understanding of the microenvironment without compromising samples. To serve your multiplex research needs, Bethyl introduces IHC PathPlex® panels to profile the complex tumor microenvironment. Each antibody has been validated for IHC and utilized in a multiplex format by our own scientists via proprietary processes to ensure the highest quality.
Simplified Development of Seven-Color Multiplex Immunohistochemistry-Immunofluorescence (mIF) Panels
With the advancement of immunotherapeutics, the need to understand the tumor microenvironment has never been more pressing. Recent advances in mIF and multispectral imaging facilitate accurate simultaneous analysis of multiple tissue markers.
Trial sizes are ideal for comparisons between suppliers or various application testings and cost effective at $99 US. Over 6,000 trial-sized antibodies are available to more than 3,300 protein targets, and new releases are continuing to be added every month.
Bethyl's purpose is to improve lives by supporting scientific discovery. This drives our complete dedication to the highest standards of product and service quality.